{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T15:16:58Z","timestamp":1786634218711,"version":"build-2736575974"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2025QC2116Z"],"award-info":[{"award-number":["ZR2025QC2116Z"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022MH016"],"award-info":[{"award-number":["ZR2022MH016"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502171"],"award-info":[{"award-number":["82502171"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) is a common and serious complication of anti-synthase syndrome (ASS), exhibiting high heterogeneity. This study aimed to stratify patients with ASS-associated ILD (ASS-ILD) based on their clinical features, high-resolution computed tomography (HRCT) findings, and specific antibody profiles. We also aimed to build a predictive model for severe ASS-ILD to help identify it more accurately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the clinical and laboratory data of 100 patients with ASS-ILD. Unsupervised clustering of clinical characteristics was done using multiple correspondence analysis (MCA) and hierarchical cluster analysis. Univariate and multivariate logistic regression were used to find independent risk factors for severe ASS-ILD, and a risk prediction model was built.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified three patient groups: Cluster 1 (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f46), the joint-predominant group, featured joint pain as the primary clinical manifestation. HRCT typically showed a non-specific interstitial pneumonia (NSIP) pattern, anti-Jo-1 antibodies were most common, and lung damage was relatively mild. Cluster 2 (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f41), the fever and Raynaud\u2019s phenomenon group, had significantly higher anti-EJ antibody levels than the other groups. Cluster 3 (\n                      <jats:italic>n<\/jats:italic>\n                      \u202f=\u202f13), the severe lung group, had much higher Warrick scores than the others. This group also had a higher frequency of a usual interstitial pneumonia (UIP) pattern on HRCT, more cases positive for anti-PL-7 or anti-PL-12 antibodies, more severe lung diffusion problems, and more heart involvement. We created and tested a combined biomarker index based on complement C3 level, rash, and age. This index demonstrated superior performance in distinguishing severe from non-severe ILD in ASS patients, independent of clinical variables such as gender, age, and smoking history.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Identifying ASS-ILD heterogeneity requires comprehensive consideration of HRCT features, antibody profiles, and clinical manifestations. The combined biomarker index (based on complement C3, rash, and age) offers an objective tool for ASS-ILD diagnosis and risk stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1798039","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:42:54Z","timestamp":1775022174000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cluster analysis and risk prediction model construction for antisynthase syndrome-associated interstitial lung disease based on clinical, imaging, and antibody characteristics"],"prefix":"10.3389","volume":"13","author":[{"given":"Jin","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoting","family":"Chao","sequence":"additional","affiliation":[{"name":"Department of Radiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Shandong Provincial Third Hospital, Shandong University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyu","family":"Yang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongzhen","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaining","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingrui","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.3390\/jcm8112013","article-title":"Influence of Antisynthetase antibodies specificities on Antisynthetase syndrome clinical Spectrum time course","volume":"8","author":"Cavagna","year":"2019","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"101503","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4453","DOI":"10.3390\/ijms25084453","article-title":"A review of Antisynthetase syndrome-associated interstitial lung disease","volume":"25","author":"Patel","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-jo-1 anti-tRNA-synthetase autoantibodies have worse survival than jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/rheumatology\/keu404","article-title":"Seronegative polyarthritis revealing antisynthetase syndrome: a multicentre study of 40 patients","volume":"54","author":"Lef\u00e8vre","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s10067-015-3023-x","article-title":"Prognostic factors in a cohort of antisynthetase syndrome (ASS): serologic profile is associated with mortality in patients with interstitial lung disease (ILD)","volume":"34","author":"Rojas-Serrano","year":"2015","journal-title":"Clin Rheumatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1183\/09031936.00104310","article-title":"Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies","volume":"37","author":"Hervier","year":"2011","journal-title":"Eur Respir J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.chest.2023.11.037","article-title":"Pictorial review of fibrotic interstitial lung disease on high-resolution CT scan and updated classification","volume":"165","author":"Brixey","year":"2024","journal-title":"Chest"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1093\/rheumatology\/keae076","article-title":"Lung imaging patterns in connective tissue disease-associated interstitial lung disease impact prognosis and immunosuppression response","volume":"63","author":"Zheng","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1177\/2397198320902667","article-title":"Antisynthetase syndrome: a distinct disease spectrum","volume":"5","author":"Huang","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4746","DOI":"10.1007\/s00330-023-09439-w","article-title":"Antisynthetase syndrome-related interstitial lung disease (ASyS-ILD): longitudinal imaging findings","volume":"33","author":"Wu","year":"2023","journal-title":"Eur Radiol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e005276","DOI":"10.1136\/rmdopen-2024-005276","article-title":"Cardiovascular events in patients with myositis: results from a French retrospective cohort","volume":"11","author":"Kasser","year":"2025","journal-title":"RMD Open"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1136\/ard-2023-225284","article-title":"Novel endotypes of antisynthetase syndrome identified independent of anti-aminoacyl transfer RNA synthetase antibody specificity that improve prognostic stratification","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1378\/chest.114.6.1623","article-title":"Relationship between abnormalities on high-resolution CT and pulmonary function in systemic sclerosis","volume":"114","author":"Diot","year":"1998","journal-title":"Chest"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/RTI.0000000000000659","article-title":"Evaluation of interstitial lung disease in idiopathic inflammatory myopathies through Semiquantitative and quantitative analysis of lung computed tomography","volume":"37","author":"Roncella","year":"2022","journal-title":"J Thorac Imaging"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.autrev.2012.06.006","article-title":"Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity","volume":"12","author":"Hervier","year":"2012","journal-title":"Autoimmun Rev"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"9679944","DOI":"10.1155\/2024\/9679944","article-title":"An observational study on the clinical characteristics and prognosis of patients with interstitial lung disease secondary to dermatomyositis and Antisynthetase syndrome","volume":"2024","author":"Lei","year":"2024","journal-title":"Int J Rheumatol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40266-019-00727-z","article-title":"Interstitial lung disease in elderly rheumatoid arthritis patients","volume":"37","author":"Messina","year":"2020","journal-title":"Drugs Aging"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/art.40574","article-title":"The lung in rheumatoid arthritis: focus on interstitial lung disease","volume":"70","author":"Spagnolo","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"35243","DOI":"10.1038\/s41598-025-22483-4","article-title":"Serum KL-6 as a biomarker to predict progression at one year in interstitial lung disease","volume":"15","author":"Bonella","year":"2025","journal-title":"Sci Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3390\/ijms26031091","article-title":"Serum KL-6 and SP-D: markers of lung function in autoimmune-related interstitial lung diseases","volume":"26","author":"Mi\u0105dlikowska","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"745233","DOI":"10.3389\/fimmu.2021.745233","article-title":"KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and Meta-analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"ref30","first-page":"1520","article-title":"High resolution computed tomography in early scleroderma lung disease","volume":"18","author":"Warrick","year":"1991","journal-title":"J Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11547-009-0367-9","article-title":"HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities","volume":"114","author":"Bellia","year":"2009","journal-title":"Radiol Med"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42358-025-00435-w","article-title":"Warrick score in rheumatoid-arthritis interstitial lung disease: a promising tool for assessing the extent and progression of lung involvement","volume":"65","author":"Karadag","year":"2025","journal-title":"Adv Rheumatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1007\/s10067-025-07443-7","article-title":"The potential of semi-quantitative and quantitative methods in predicting progression in rheumatoid arthritis-associated interstitial lung disease","volume":"44","author":"Temiz Karadag","year":"2025","journal-title":"Clin Rheumatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1165\/rcmb.2023-0171ED","article-title":"Aging delays lung repair: insights from omics analysis in mice with pulmonary fibrosis","volume":"69","author":"Liang","year":"2023","journal-title":"Am J Respir Cell Mol Biol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2200957","DOI":"10.1183\/13993003.00957-2022","article-title":"Idiopathic pulmonary fibrosis: state of the art for 2023","volume":"61","author":"Podolanczuk","year":"2023","journal-title":"Eur Respir J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/thorax-2024-222060","article-title":"Epithelial damage and ageing: the perfect storm","volume":"80","author":"Hewitt","year":"2025","journal-title":"Thorax"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.1212\/WNL.0000000000009727","article-title":"Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: study of 121 cases","volume":"95","author":"Allenbach","year":"2020","journal-title":"Neurology"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1056\/NEJM200104053441406","article-title":"Complement first of two parts","volume":"344","author":"Walport","year":"2001","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12931-023-02657-2","article-title":"The complement cascade in lung injury and disease","volume":"25","author":"Detsika","year":"2024","journal-title":"Respir Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1080\/25785826.2024.2370083","article-title":"Low serum complements in idiopathic inflammatory myositis: clinical features and impact on the prognosis","volume":"47","author":"Nomura","year":"2024","journal-title":"Immunol Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798039\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T05:42:55Z","timestamp":1775022175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798039\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":40,"alternative-id":["10.3389\/fmed.2026.1798039"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1798039","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1798039"}}